Show results for
Refine by
Advanced Exosomal Rna Sequencing Software In Europe
16 software items found
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Next-generation sequencing (NGS) of the human exome has the potential to identify pathogenic variants responsible for complex phenotypes associated with rare ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Next-generation sequencing (NGS) has the potential to revolutionize the diagnosis and treatment of cancers and rare diseases but creates extremely large, complex, and noisy datasets for analysis. Without the right analytical technology, pinpointing causative variants and obtaining actionable insights from NGS data requires specialist skills, multiple resources, and considerable time. The ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Metabolic disorders are a major cause of morbidity and mortality, representing a growing health concern worldwide. Over the last decade, substantial progress has been made in the discovery of genetic variants influencing a range of metabolic diseases.1 The advances in next generation sequencing (NGS) technologies have contributed to elucidation of the pathogenic role of variants associated with ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Hematological tumors represent the fourth most frequent cancer type in the developed world. In addition to the continuously evolving clinical guidelines2, harnessing of all the available information when investigating hematological disorders into meaningful insights can be outdated, inaccurate, costly, and time-consuming. This ultimately risks limiting researchers’ productivity, thus ...
by:Sapio Sciences based inBaltimore, MARYLAND (USA)
With our LIMS configurable technology and workflow templates, projects are completed in a fraction of the time and cost of standard LIMS ...
by:Seven Bridges Genomics based inCharlestown, MASSACHUSETTS (USA)
The representation of the human reference genome as a linear haploid DNA sequence poses limitations when trying to incorporate the known genetic diversity of human populations. This has led to the development of graph-based references, able to naturally represent all polymorphisms, including insertions, deletions, and structural ...
by:Qlucore AB based inLund, SWEDEN
Qlucore's clinical diagnostics solutions for multi-omics companion and precision diagnostics include AI-powered, disease-specific machine learning based classifier models and are combined with patient-friendly visualizations in a an easy-to-use and cost-effective software solution which integrates with a wide range of data generating techniques and instruments. ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Hereditary causes account for ∼10% of cancer cases, and an estimated 20% of cancer patients have a family history of cancer. Identification of an individual with a suspected hereditable cancer can lead to additional examinations and help formulate the most appropriate prevention strategies. Evaluating the predisposition to develop inherited cancer depends on the ability to characterize genes ...
Manufactured by:CENTOGENE N.V. based inRostock, GERMANY
Analyze, interpret, and report genomic variants with our decentralized diagnostic solution – no matter where you are located. CentoCloud is a cloud-based Software as a Service (SaaS) platform specifically designed for the rapid bioinformatic analysis and interpretation of Next-Generation-Sequencing (NGS) data based on CENTOGENE’s proprietary Biodatabank and external reference ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Genomic profiling is driving precision oncology. From targeted to comprehensive solutions, Next-Generation-Sequencing (NGS) offers the capacity to simultaneously analyze a select set of genes, regions, and biomarkers based on known involvement across solid tumor such as lung, colon, breast, melanoma, gastric, and ovarian cancers. However, as tests either expand or become more specialized, ...
by:NEC OncoImmunity AS based inOslo, NORWAY
The NEC Immune Profiler Provides an Holistic Approach to Antigen Presentation Prediction. NEC OncoImmunity AS has developed an AI engine for its clinical projects, known as the NEC Immune Profiler, that predicts from next generation sequencing data true neoantigens for personalized cancer immunotherapy and cancer immunotherapy ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Confidently assess genetic variants predisposing to cancer. Hereditary causes account for ∼10% of cancer cases, and an estimated 20% of cancer patients have a family history of cancer.1 Identification of an individual with a suspected hereditable cancer can lead to additional examinations and help formulate the most appropriate prevention strategies. Evaluating the predisposition to develop ...
Manufactured by:OncoDNA S.A. based inGosselies, BELGIUM
Order OncoDNA's solutions, browse your patients' history and receive your personalised report on treatment recommendations. When you join OncoSHARE, you become a member of an active network gathering together more than 13,000 patients and oncologists. Regardless of whether the information concerns patient health or payment, we take every precaution to ensure your security. OncoSHARE is used by ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Deeper genomic insights, fewer missed opportunities. CGP enables clinical researchers to identify actionable variants and biomarkers across hundreds of genes using a single solution. The SOPHiA DDMTM Platform offers decentralized, in-house next generation sequencing (NGS) applications that help maximize insights from CGP data by leveraging advanced analytical capabilities, intutive interpretation ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Rise above the noise to see what truly matters. Elevate your precision oncology program. Push the boundaries of your in-house liquid biopsy capabilities with MSK-ACCESS® powered with SOPHiA DDM™, a decentralized version of the rigorously validated cell-free DNA (cfDNA) assay developed and used in clinical routine by Memorial Sloan Kettering Cancer Center (MSK)1,2. Discover an innovative ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Enabling novel fusion detection in small samples to improve lung cancer management. Sensitive novel fusion detection optimized for small lung cancer FFPE biopsies enhance patient care. SOPHiA DDM™ Dx RNAtarget Oncology Solution (ROS) is a CE-marked in vitro diagnostic (IVD) application based on next-generation sequencing (NGS) enabling accurate and sensitive detection of novel ...